Find Hot

Enterprise hot news

Category: Kossel

  • Seledora® Coronary Scoring Balloon Catheter– Product Overview

    “Precise lesion preparation” and “vascular functional restoration” are the main themes in current coronary interventional therapy.

    Compared with common balloon angioplasty, which compresses plaques in a disordered manner, scoring balloons offer a more targeted solution. On the one hand, the scoring elements focus pressure on the lesion, enabling controlled plaque modification and reducing the risk of irregular dissections that could restrict blood flow. On the other hand, for moderate to severe, especially circumferential calcified lesions that are often hard to cross with other devices, scoring balloons can embed their elements into the plaque and dilate it at low pressure. This approach helps to gradually open the lesion, creating favorable conditions for further lumen preparation and maintenance—— achieving true precise lesion preparation.

    Seledora® Coronary Scoring Balloon Catheter

    Seledora® Coronary Scoring Balloon Catheter

    The Seledora® Coronary Scoring Balloon Catheter features a deliverability profile of 0.0165″, equivalent to a conventional pre-dilatation balloon. It is equipped with three triangular nylon scoring ridges, each 0.42 mm in height, evenly distributed at 120° intervals along the balloon’s proximal and distal ends. This design ensures excellent lumen gain while maintaining good crossability.

    Balloon Catheter

    Ex Vivo Simulation Results
    The Seledora® scoring balloon demonstrated uniform and consistent scoring morphology aligned with the direction of blood flow, indicating effective and controlled plaque modification.

    Seledora® scoring balloon

    Seledora® scoring balloon2

    Seledora® scoring balloon3

    Clinical Benefits

    The immediate lumen gain in the test group showed no statistically significant difference from the control group, confirming the non-inferiority of the Seledora device. Safety and secondary efficacy outcomes were also comparable between the two groups.

    Specifications Chart

    PTCA BALLOON DILATATION CATHETER

    By enabling low-pressure, focused dilatation and directional, controlled plaque scoring, the Seledora® Coronary Scoring Balloon Catheter facilitates effective lumen gain and precise lesion preparation. This paves the way for optimized lumen modification and maintenance, enhances the drug release performance of DES (drug-eluting stents) and DCB (drug-coated balloons), reduces restenosis, ensures long-term treatment efficacy, and ultimately benefits the patient.

  • Seledora Coronary Scoring Balloon Catheter

    Seledora Coronary Scoring Balloon Catheter

    Seledora® Coronary Scoring Balloon Catheter is Now Available
    Low-pressure focused dilation, safe and effective, flexible and efficient, helping to fully pre-dilate the coronary artery

  • Celebratory News丨Selethru® PTCA balloon dilatation catheter has obtained the CE MDR certification

    Celebratory News丨Selethru® PTCA balloon dilatation catheter has obtained the CE MDR certification

    Recently, Kossel’s independently developed Selethru® PTCA balloon dilatation catheter has successfully passed the EU Medical Device Regulation (MDR) certification, marking that the product has met the highest international standards in terms of safety, effectiveness and clinical performance.

    Selethru®-PTCA-balloon-dilatation-catheter

    Europe is a globally important medical device market. The acquisition of MDR certification has provided strong support for Kossel to continue its in-depth expansion into Europe and its affiliated markets. In the future, the company will continue to advance the “Local Base, Global Reach” overseas strategy, strengthen cooperation with global medical institutions and experts, and enable more patients to benefit from Chinese medical devices!

  • Deepening Latin American Ties — Kossel Medtech Strikes a New Chord in the Land of Samba

    Deepening Latin American Ties — Kossel Medtech Strikes a New Chord in the Land of Samba

    Hospitalar 2025 | São Paulo, Brazil | May 20–23

    Hospitalar, one of South America’s most influential healthcare exhibitions, concluded successfully in São Paulo. Leveraging Brazil’s strategic position in Latin America, the event has become a key platform for regional medical integration and international collaboration.


    At this major event, Kossel Medtech showcased a portfolio of flagship products and localized solutions—highlighting our latest innovations in vascular intervention to a global audience.

    Brazil, home to Latin America’s largest healthcare market, is a core part of Kossel’s strategic expansion. Our Falspeed® Peripheral PTA Balloon Catheter and Falexpand® High-Pressure Peripheral Balloon Catheter have already been certified by ANVISA, laying a strong foundation for local growth.

    During the exhibition, Kossel Medtech welcomed partners and distributors from Brazil, Argentina, Mexico, Colombia, Peru, Chile, South Korea, and Ecuador. Our high-performance products and globally trusted solutions drew widespread interest, further solidifying our presence and reputation across Latin America.

    Looking ahead, Kossel Medtech will continue to advance innovation in vascular intervention, accelerate our global market strategy, and deliver high-quality, application-driven solutions to healthcare professionals worldwide.

    Innovation Without Borders. Reach Without Limits.

    #Kossel Medtech #Hospitalar2025 #LatinAmericaHealthcare #MedTechInnovation #PeripheralIntervention #GlobalExpansion #ANVISA #MedicalDevices #BrazilMedTech #VascularSolutions #HealthcareExhibition #Falspeed #Falexpand #LocalBaseGlobalReach #LifeSciences

  • Cathios® CARDIAC ABLATION CATHETER

    Cathios® CARDIAC ABLATION CATHETER

    Cathios® CARDIAC ABLATION CATHETER

    A. Easy Control
    1:1 twisting force feedback makes tip placement convenient and quick

    B. Excellent Tip and Special design Curve Part
    16X2 strands wire braid curve part and brilliant tip help catheter stay close to cardiac structure

    C. Adjust Precisely
    It is easy to locate the target points of heart with accurate bending of head part of catheter

    D. Comfortable Handle
    1. Ergonomic design help catheter push through the vessel conveniently
    2. Surface is skidproof and comfortable to hold

    E. Compatibility
    The extension cable is designed with various interfaces, suitable for different devices

  • Falspeed® PTA Balloon Dilatation Catheter

    PTA balloon catheter is mainly used for limb blood vessels, extended to the arteries, such as renal artery, coronary artery, and  vein, such as the expansion of the vena cava stenosis, and treatment of artificial blood vessels, transplant vascular stenosis or occlusion.

    1. A wide range of diameters and lengths are available, covering different clinical demands

    2. The 3 wing or 6 wing folding techniques make the balloon’s profile small, raising passing capability for challenging stenosis

    3. The soft and tapered tip helps the balloon get through lesions easily

    4. The hydrophilic coating reduces friction during pushing process

  • Cathlink Electrode Lead Introducer Sheath

    Cathlink Electrode Lead Introducer Sheath

    Dedicated sheath for electrode leads – reduces procedural complexity and increases success rates.

    For more info,please contact us at :

    Web:https://www.kossel-medical.com/

    Email:nicole.ma@kosselmed.com

    WhatsApp:+86 131 4777 1518

  • Misatin® Hydrophilic Guidewire

    Misatin® Hydrophilic Guidewire

    Misatin® Hydrophilic Guidewire

    •  Long tapered tip for easy navigation.
    •  NiTi mandrel for stability and kink resistance.
    •  Tungsten polymer jacket for visibility and control.
    •  Hydrophilic coating for smooth passage and reduced injury.

  • The Clinical Research of Mistent® Coronary Drug Eluting Stent System

    The Clinical Research of Mistent® Coronary Drug Eluting Stent System

    一、Stent Design

    The biodegradable coating (PLGA polymer combined with sirolimus crystals) was realized based on supercritical fluid technology, which gave birth to the Mistent® coronary drug-eluting stent. It has two distinctive features: “Quick Healing” and “Long-lasting Drug Efficacy”. The biodegradable polymer enables rapid endothelialization and reduces chronic inflammation and the occurrence of stent thrombosis; the controlled and slow-release of sirolimus drug crystals for up to 9 months reduces late lumen loss of the stent.

    Mistent®-Coronary-Drug-Eluting-Stent-System1

    二、Clinical Study

    Mistent® coronary drug-eluting stent system has undergone numerous clinical studies worldwide, involving over 2,000 patients.

    Mistent®-Coronary-Drug-Eluting-Stent-System2

    DESSOLVE I

    The DESSOLVE I study is a multicenter, single-arm clinical trial involving 30 patients. It assesses the device’s performance through coronary angiography, optical coherence tomography (OCT), and intravascular ultrasound (IVUS) and evaluates its safety through major adverse cardiac events (MACE) after MiStent SES implantation.
    At different time points, late lumen loss (LLL) was measured by angiography. The results indicated that during the period of 6 months and 18 months, there was no progression of late lumen loss after implantation in these patients (0.9 ± 0.11 and 0.09 ± 0.15 respectively).

    Mistent®-Coronary-Drug-Eluting-Stent-System23

    In the OCT analysis of results of the 4th, 6th and 8th months, thin and uniform vascular endothelial coverage was observed at the stent strut sites. The stent strut coverage occurred earlier and had a high coverage rate (93% at the 4th month, 97% at the 6th month, 96% at the 8th month, and 100% at the 18th month).

    Mistent®-Coronary-Drug-Eluting-Stent-System235

    DESSOLVE II

    DESSOLVE II is a randomized clinical trial that compared MiStent SES and Endeavor Sprint zotarolimus-eluting stents. A total of 184 subjects from 26 centers were randomly assigned in a 2:1 ratio to receive MiStent SES or Endeavor ZES implantation.
    The results showed that MiStent SES was superior to Endeavor ZES, with a significant reduction in late lumen loss (0.27 ± 0.46 and 0.58 ± 0.41, p < 0.001).

    Mistent®-Coronary-Drug-Eluting-Stent-System

    In the subgroup analysis, patients underwent OCT and endothelial function analysis at the 9th month. The OCT analysis indicated that the proportion of endothelial coverage within the stent struts was high (99.7%), and there were no signs of poor stent strut adherence (0%). The endothelial function test showed that endothelial function was preserved. These results indicated that the vascular healing was good and the endothelial function returned to normal.
    At 5 years after the operation, the incidences of major adverse cardiovascular events (MACE) in the MiStent group and the Endeavor control group were 15.1% and 22.0% respectively, and the incidence of target lesion revascularization (TLR) was 3.4% in both groups.

    Mistent®-Coronary-Drug-Eluting-Stent-System6

    DESSOLVE III

    DESSOLVE III study is a prospective, randomized, 1:1 controlled, single-blind, multicenter study that compared the clinical outcomes of MiStent SES and XIENCE in the “real-world all-comer” patient population at the 12th month.

    Mistent®-Coronary-Drug-Eluting-Stent-System7

    This study demonstrated that MiStent SES was non-inferior to Xience, and that the TLF, TLR, ST and TVMI of MiStent SES showed a decreasing trend.

    Mistent®-Coronary-Drug-Eluting-Stent-System8

    Mistent®-Coronary-Drug-Eluting-Stent-System9

    Mistent®-Coronary-Drug-Eluting-Stent-System10

    Mistent®-Coronary-Drug-Eluting-Stent-System11

    Mistent®-Coronary-Drug-Eluting-Stent-System12

  • PAIRS 2025 | Expanding Horizons, Connecting Globally

    PAIRS 2025 | Expanding Horizons, Connecting Globally

    We had a fantastic time at PAIRS 2025, held from April 9–12 at the Dubai World Trade Centre!

    balloon catheter

    As a company committed to innovation in vascular intervention, Kossel proudly showcased our flagship products from three key product lines: Peripheral Intervention, Coronary Intervention, and Cardiac Electrophysiology. It was a great opportunity to demonstrate our R&D strength and global vision in front of a truly international audience.

    ptca balloon catheter stent system coronary stent system

    PAIRS, established in 2006, is the largest interventional radiology conference in the Arab region. We connected with doctors and partners from Saudi Arabia, Iraq, Turkey, Egypt, the UAE, Kuwait, Russia, South Africa, Mauritius, and more during the event. These conversations opened up new doors for collaboration and strengthened existing relationships.

    pta-balloon-catheter balloon-catheter

    ptca-balloon-catheter coronary-stent-system

    Our coronary and peripheral balloon products are already being used in several countries across the region, and we’re honored to see them gaining real clinical recognition. With innovation at our core, Kossel is committed to listening to global needs, pushing forward with R&D, and delivering high-quality solutions worldwide.
    This marks another important step in our strategy to expand across the Middle East, North Africa, and neighboring regions. Looking ahead, we remain rooted in China while growing globally—committed to delivering high-quality, innovative interventional solutions to doctors and patients around the world.